Skip to main content

ERRATUM article

Front. Immunol., 13 December 2022
Sec. Molecular Innate Immunity
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.1097810

Erratum: Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality

This article is an erratum on:

  1. Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on:
Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality.

By Schneider F, Le Borgne P, Herbrecht J-E, Danion F, Solis M, Hellé S, Betscha C, Clere-Jehl R, Lefebvre F, Castelain V, Goumon Y and Metz-Boutigue M-H (2022)  13:985472. doi: 10.3389/fimmu.2022.985472

Due to a production error, there was a mistake in Figure 1 as published. The wrong figure was inserted as Figure 1. The corrected Figure 1 appears below. The publisher apologizes for this mistake.

FIGURE 1
www.frontiersin.org

Figure 1 Flow chart of the study. Study participants (n=100) were screened for participation during the first surge of the disease (March to May 2020) among 547 patients admitted for COVID either to the emergency department or to the ICU. Informed consent for participation was obtained in 49 COVID+ ICU+ patients, and in 24 COVID+ICU- patients, which were then admitted to the infectious disease department. In parallel, 11 participants were recruited in our staff (as healthy controls, COVID-ICU-), and so were 16 COVID-ICU+ patients that were admitted for non-COVID multiple organ failure requiring mechanical ventilation support.

Keywords: Innate immunity, COVID, Catestatin, Chromogranin A, hypoxia, critically ill, nosocomial disease

Citation: Frontiers Production Office (2022) Erratum: Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality. Front. Immunol. 13:1097810. doi: 10.3389/fimmu.2022.1097810

Received: 14 November 2022; Accepted: 14 November 2022;
Published: 13 December 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.